Given that CAS are increasingly recognised in migraine [225] and can present in the premonitory phase before headache [80], combined with emerging evidence that VIP may, in fact, be involved in the headache phase of migraine, VIP may emerge as a potential therapeutic target in migraine again in the future. This evidence concerns the gene VIP and migraine disorder.